The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS
Open accessThe DOI matches its Crossref record; 117 of the 120 references it cites were found in a registry or an index.
Abstract
X-linked juvenile retinoschisis (XLRS) is an early-onset progressive inherited retinopathy affecting males. It is characterized by abnormalities in the macula, with formation of cystoid retinal cavities, frequently accompanied by splitting of the retinal layers, impaired synaptic transmission of visual signals, and associated loss of visual acuity. XLRS is caused by loss-of-function mutations in the retinoschisin gene located on the X chromosome (RS1, MIM 30083). While proof-of-concept studies for gene augmentation therapy have been promising in in vitro and rodent models, clinical trials in XLRS patients have not been successful thus far. We performed a systematic literature investigation using search strings related to XLRS and gene therapy in in vivo and in vitro models. Three rounds of screening (title/abstract, full text and qualitative) were performed by two independent reviewers until consensus was reached. Characteristics related to study design and intervention were extracted from all studies. Results were divided into studies using (1) viral and (2) non-viral therapies. All in vivo rodent studies that used viral vectors were assessed for quality and risk of bias using the SYRCLE’s risk-of-bias tool. Studies using alternative and non-viral delivery techniques, either in vivo or in vitro, were extracted and reviewed qualitatively, given the diverse and dispersed nature of the information. For in-depth analysis of in vivo studies using viral vectors, outcome data for optical coherence tomography (OCT), immunohistopathology and electroretinography (ERG) were extracted. Meta-analyses were performed on the effect of recombinant adeno-associated viral vector (AAV)-mediated gene augmentation therapies on a- and b-wave amplitude as well as the ratio between b- and a-wave amplitudes (b/a-ratio) extracted from ERG data. Subgroup analyses and meta-regression were performed for model, dose, age at injection, follow-up time point and delivery method. Between-study heterogeneity was assessed with a Chi-square test of homogeneity (I2). We identified 25 studies that target RS1 and met our search string. A total of 19 of these studies reported rodent viral methods in vivo. Six of the 25 studies used non-viral or alternative delivery methods, either in vitro or in vivo. Of these, five studies described non-viral methods and one study described an alternative delivery method. The 19 aforementioned in vivo studies were assessed for risk of bias and quality assessments and showed inconsistency in reporting. This resulted in an unclear risk of bias in most included studies. All 19 studies used AAVs to deliver intact human or murine RS1 in rodent models for XLRS. Meta-analyses of a-wave amplitude, b-wave amplitude, and b/a-ratio showed that, overall, AAV-mediated gene augmentation therapy significantly ameliorated the disease phenotype on these parameters. Subgroup analyses and meta-regression showed significant correlations between b-wave amplitude effect size and dose, although between-study heterogeneity was high. This systematic review reiterates the high potential for gene therapy in XLRS, while highlighting the importance of careful preclinical study design and reporting. The establishment of a systematic approach in these studies is essential to effectively translate this knowledge into novel and improved treatment alternatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic structure representing the retinoschisin (RS1) gene (A), protein diagram (B), the quaternary structure of the protein (C), and hallmarks of X-linked juvenile retinoschisis (XLRS) (D). (A) (Adapted from Hahn et al. [4]). An overview of RS1 shows the localization and variants within the gene. Colored boxes represent the six exons, and the numbers within the boxes represent their size in nucleotides. The type of variant is presented in the legend, and the frequency and distribution are described within the gene structure. Splice site (n = 38), missense (n = 101), and deletion variants (n = 11) are the three most common variants. (B) Overview of the RS1 protein, featuring the signal peptide domain, the RS1 domain, the discoidin domain and the C-terminal domain. (C) The top and side view of the octamer and double octamer. (D) Fundus photograph of a 35-year old patient with a hemizygous c.428A > T p.(Asp143Val) mutation in the RS1 gene patient with XLRS, and optical coherence tomography image showing macular schisis (asterisk) in this patient with XLRS.](https://figures.cochat.ai/paper-figures/2b6d4ed5e9c04e7180b66e92e65ebac9/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-1.jpg)

![Figure 3 All in vivo studies were assessed on their risk of bias using the SYRCLE tool [69]. (A) The studies were assessed on whether any information was provided about ethical approval, conflicts of interest, calculation of sample sizes, blinding, or randomization. (B) The studies were assessed on possible risk of selection, performance, detection, outcome reporting, attrition and other biases. When the contralateral eye was used as the (internal) control, questions for random housing and allocation concealment were answered with not-applicable (N/A). Most studies received an unclear risk-of-bias score, due to a lack of reporting of essential quality indicators.](https://figures.cochat.ai/paper-figures/50ae7ab620ce4c60b2413a1e899c349a/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-3.jpg)


![Figure 6 The overall effect size of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on a-wave amplitudes with integrated dosage subgroup analysis. The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this meta-analysis were Bush2016 [85], Scruggs2022 [88], Min2005 [77], and Marangoni2017 [87]. The results are staggered per subgroup (total dose smaller than 4 × 109 viral genomes/eye (vg/eye) and larger than 4 × 109 vg/eye). The black circles represent the overall subgroup effect size, and the green diamond represents the overall weighted effect size. The black dashed line indicates the null effect. The left side of the null effect line favors the control, whereas the right side of the null effect line favors treatment. The overall effect size (0.75 [0.56, 0.94]) was computed with a random effects model and is represented by a green diamond and dashed line. Included studies were assessed for homogeneity with a Chi-square test and were not found to be highly heterogeneous (I2 = 17.1%). SMD = standardized mean difference, CI = confidence interval.](https://figures.cochat.ai/paper-figures/8bea9c26adce47648e282ee554eabb8b/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-6.jpg)
![Figure 7 The overall weighted effect size of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on the b-wave amplitude. The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this analysis were Min2005 [77], Molday2006 [78], Janssen2008 [80], Byrne2014 [54], Bush2016 [85], Marangoni2017 [87], and Scruggs2022 [88]. The standardized mean differences (SMDs) with 95% confidence intervals (CI) of each experimental group are displayed in a forest plot. The dashed black line represents no treatment effect. Values left of the null effect line favor control, whereas values right of the null effect line favors treatment. The overall effect size (1.44 [1.11, 1.77]) was computed with a random-effects model and is represented by a green diamond and dashed line. Included studies were assessed for homogeneity with a Chi-square test and were found to be highly heterogeneous (I2 = 76.5%).](https://figures.cochat.ai/paper-figures/79813cddee0b4a289c864a7cc2f733e0/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-7.jpg)
![Figure 8 The effect sizes of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on the b-wave amplitude for subgroups mouse model, delivery method, dose, age at injection, and follow-up time point. The black dashed line indicates the null effect. Values left of the null effect line favor the control, whereas values right of the null effect line favor the treatment. The overall effect size (1.44 [1.11, 1.77]) was computed with a random-effects model and is represented by a green diamond and dashed line. The between-study heterogeneity was high (I2 = 76.5%), and therefore these subgroup analyses serve for orientational purposes only. Rs1h = retinoschisin, KO = knock-out, IVI = intravitreal injection, SRI = subretinal injection, M = months of age, MPI = months post-injection, SMD = standardized mean difference, CI = confidence interval.](https://figures.cochat.ai/paper-figures/9722fc9a5485427297d9d0f3fd2d9f66/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-8.jpg)
![Figure 9 The overall weighted effect size of AAV-mediated gene augmentation therapy on the ratio between the b- and a-wave amplitudes (b/a-ratio). The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this analysis were Bush2016 [85], Park2009 [82], and Marangoni2017 [87]. The results are staggered per subgroup (total dose smaller than 4 × 109 viral genomes/eye (vg/eye) and larger than 4 × 109 vg/eye). The black circles represent the overall subgroup effect size, and the green diamond represents the overall weighted effect size. The black dashed line indicates the null effect. Values left of the null effect line favor control, whereas values right of the null effect line favors treatment. The overall effect size (1.08 [0.42, 1.74]) was computed with a random-effects model and is represented by a green diamond and dashed line. The black circles indicate the overall subgroup effect size. A Chi-square test of homogeneity revealed high levels of between-study heterogeneity (I2 = 90.7%). SMD = standardized mean difference, CI = confidence interval.](https://figures.cochat.ai/paper-figures/234e63e12b584ff69837ea02d2eadcde/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-9.jpg)

![Figure 11 The classification of alternative delivery and non-viral delivery methods. The first classification is alternative delivery and non-viral delivery methods. In the former, the exosome-associated adeno-assiocated viral vectors (AAVs) are classified [93]. Within the non-viral methods category, a second classification can be made: chemical and physical methods. The physical methods contain the electroporation method [58], while the chemical methods can be divided into organic (solid lipid nanoparticles [63,95]) or inorganic (dual supramolecules nanoparticles [96] and carboxylated nanodiamonds [97]) vectors. In each category, a schematic representation of the vectors used for RS1 or gene editing constructs delivery is included to illustrate the building blocks used in each vector. Dual supramolecular nanoparticle and carboxylated nanodiamond representations have been adapted from Chou et al. and Yang et al., respectively [96,97]. Outlined with a yellow line are the studies designed for gene augmentation, whereas those designed for gene editing are marked with a green line. XLRS = X-linked juvenile retinoschisis, RS1 = retinoschisin, ad = adamantane-grafted, PEG = polyethylene glycol, TAT = adenosine-5’-rp-alpha-thio-triphosphate, CD-PEI = carbon dot-polyethylenimine, GFP = green fluorescent protein, sgRNA = single guide RNA.](https://figures.cochat.ai/paper-figures/45588f2d31a54ac49e396145d126cc3d/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-11.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, Xlinked retinoschisis demonstrates increased retinal fragility, making the detachment of posterior hyaloid and subretinal injection highly chal lenging (van der Veen et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as van der Veen et al., 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SYRCLE’s risk of bias tool for animal studies
Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-43 · Cited by 4,415 · cited 2×
“Secondly, risk-of-bias assessment was conducted based on ten entries, which aimed to evaluate selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases [69].”
MethodAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444 · cited 2×
“This is due to the recent advances in AAV capsid research, their high transduction efficiency, high biosafety, reduced immunogenicity and their long-term and stable genome expression [44–46].”
BackgroundInfluentialNonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Despite these limitations, AAVs were approved by the Food and Drug administration (FDA) and European Medicine Agency (EMA) to treat RPE65 -associated Leber’s congenital amaurosis, and are currently used in ongoing clinical trial for a broad range of inherited retinal diseases [48–51].”
BackgroundBase editing: precision chemistry on the genome and transcriptome of living cells
Rees, H. A., & Liu, D. R. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0059-1 · Cited by 1,675
An atlas of the protein-coding genes in the human, pig, and mouse brain
Sjöstedt, E., Zhong, W., Fagerberg, L., Karlsson, M., Mitsios, N., Adori, C., Oksvold, P., Edfors, F., Limiszewska, A., Hikmet, F., et al. (2020) · Science · doi:10.1126/science.aay5947 · Cited by 1,151
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“While non-viral vectors have been demonstrated to have lower immunogenicity and toxicity, they generally also show lower transduction efficiency; as a consequence, further optimization is still required [65,114].”
BackgroundLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“Nevertheless, and despite the eye’s relative immune privilege, immune responses to high AAV doses are still reported in in vivo studies [55,56].”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Positional cloning of the gene associated with X-linked juvenile retinoschisis
Sauer, C. G., Gehrig, A., Warneke-Wittstock, R., Marquardt, A., Ewing, C. C., Gibson, A., Lorenz, B., Jurklies, B., & Weber, B. H. F. (1997) · Nature Genetics · doi:10.1038/ng1097-164 · Cited by 497 · cited 1×
“The active biological conformation of the protein RS1 is a homo-oligomeric octamer that is secreted from both photoreceptors and bipolar cells [14,21–23].”
BackgroundNon-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects
Zu, H., & Gao, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00608-7 · Cited by 475 · cited 1×
“These non-viral vectors appear to have less immunotoxicity, in contrast to AAV or related viral vectors potentially [66].”
BackgroundNon-viral gene delivery systems
Davis, M. E. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00294-x · Cited by 419
X-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms
Molday, R. S., Kellner, U., & Weber, B. H. F. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.12.002 · Cited by 331 · cited 2×
“The schisis is seen in both the nuclear and plexiform layers of the retina and can involve the inner, middle and outer retinal layers [4,11].”
BackgroundStubbs, J. D., Lekutis, C., Singer, K. L., Bui, A., Yuzuki, D., Srinivasan, U., & Parry, G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8417 · Cited by 313
Kawakami, A., Kitsukawa, T., Takagi, S., & Fujisawa, H. (1996) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(199601)29:1<1::aid-neu1>3.0.co;2-f · Cited by 291
Emerging non-viral vectors for gene delivery
Wang, C., Pan, C., Yong, H., Wang, F., Bo, T., Zhao, Y., Ma, B., He, W., & Li, M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02044-5 · Cited by 286 · cited 2×
“Non-viral vectors encapsulate and transport DNA, mRNA, small interfering RNA (siRNA) and microRNA (miRNA) [57].”
BackgroundDiscoidin domain receptors: structural relations and functional implications
Vogel, W. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.9001.s77 · Cited by 269 · cited 1×
“The discoidin domain mediates communication between cells and tissues [24] and is shared by several well-conserved extracellular cell surface proteins [25–31].”
BackgroundCukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268 · cited 2×
“…gene augmentation therapy AAV8-scRS/IRBPhRS (scRS = self-complementary vector genome containing a modified human retinoschisin promoter; IRBP = interphotoreceptor retinoid-binding protein enhancer) in nine patients failed to improve symptoms in all but one (ClinicalTrial.gov: NCT02317887) [68].”
BackgroundNovel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267 · cited 1×
“These were, firstly, AAV2tYF, which has three tyrosine residues mutated to phenylalanine (Y to F) residues on the surface of the AAV2 capsid [89].”
BackgroundGeorge, N. D., Yates, J. R., & Moore, A. T. (1995) · British Journal of Ophthalmology · doi:10.1136/bjo.79.7.697 · Cited by 250
Exosome-mediated delivery of gene vectors for gene therapy
Duan, L., Xu, L., Xu, X., Qin, Z., Zhou, X., Xiao, Y., Liang, Y., & Xia, J. (2021) · Nanoscale · doi:10.1039/d0nr07622h · Cited by 238 · cited 1×
“The outcomes used to evaluate the transfection capacity were variable and are included in Table 7 (for studies following the RS1 integration strategy) and in Table 8 (for studies following the RS1 gene editing strategy), with the evaluation time points after transfection.”
MethodTakagi, S., Hirata, T., Agata, K., Mochii, M., Eguchi, G., & Fujisawa, H. (1991) · Neuron · doi:10.1016/0896-6273(91)90268-5 · Cited by 227
The Retinoschisis Consortium (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.7.1185 · Cited by 226
Self-citationRecombinant Adeno-associated Virus Transduction and Integration
Schultz, B. R., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.103 · Cited by 215 · cited 1×
“Different AAV serotypes have distinct cellular tropism and transduction capacities, depending on their interaction with membrane receptors and cellular mechanisms for uptake and trafficking [52].”
BackgroundX-linked retinoschisis: A clinical and molecular genetic review
Tantri, A., Vrabec, T. R., Cu-Unjieng, A., Frost, A., Annesley, W. H., & Donoso, L. A. (2004) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2003.12.007 · Cited by 211 · cited 1×
“On fundus examination, a spoke-wheel pattern of microcystic changes radiating outwards from the foveola is typically seen [10] (Figure 1D).”
BackgroundWeber, B. H. F., Schrewe, H., Molday, L. L., Gehrig, A., White, K. L., Seeliger, M. W., Jaissle, G. B., Friedburg, C., Tamm, E., & Molday, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092528599 · Cited by 211 · cited 4×
“%) was the Rs1h -KO mouse developed by Zeng et al. [71] followed by the Weber Rs1h − /y mouse [70] (26”
BackgroundMethodInfluentialKlimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210 · cited 1×
“One group used AAVshH10, which is derived from the AAV6 shuffled library and primarily targets Müller cells [92].”
MethodExpression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells
Molday, L. L., Hicks, D., Sauer, C. G., Weber, B. H. F., & Molday, R. S. (2001) · PubMed · doi:10.5283/epub.35825 · Cited by 200
Expression of a Cell Adhesion Molecule, Neuropilin, in the Developing Chick Nervous System
Takagi, S., Kasuya, Y., Shimizu, M., Matsuura, T., Tsuboi, M., Kawakami, A., & Fujisawa, H. (1995) · Developmental Biology · doi:10.1006/dbio.1995.1208 · Cited by 198
Physical Non-Viral Gene Delivery Methods for Tissue Engineering
Mellott, A. J., Forrest, M. L., & Detamore, M. S. (2013) · Annals of Biomedical Engineering · doi:10.1007/s10439-012-0678-1 · Cited by 196 · cited 1×
“Non-viral methods can be classified as chemical, relying on the capacity of positive lipids, peptides or polymers to introduce the negatively charged DNA of interest into cells [61] or physical, by using temperature or electrical shock to achieve nucleic acid integration [62].”
BackgroundZeng, Y., Takada, Y., Kjellstrom, S., Hiriyanna, K., Tanikawa, A., Wawrousek, E., Smaoui, N., Caruso, R., Bush, R. A., & Sieving, P. A. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0576 · Cited by 191 · cited 7×
“Of these internal controls, two were sham-injected [17,71,84], and the rest were directly compared to the untreated fellow eye.”
BackgroundMethodInfluentialSubretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases
Peng, Y., Tang, L., & Zhou, Y. (2017) · Ophthalmic Research · doi:10.1159/000479157 · Cited by 175 · cited 1×
“Post-developmental adult vector delivery at 13 weeks was able to restore RS1 expression and rescue the ERG waveform and improve the scotopic b-wave by 6 months of age, but it did not lead to any improvements in retinal morphology or photoreceptor survival [71].”
BackgroundStructure of the gene for human coagulation factor V
Cripe, L. D., Moore, K. D., & Kane, W. H. (1992) · Biochemistry · doi:10.1021/bi00130a007 · Cited by 174
Min, S. H., Molday, L. L., Seeliger, M. W., Dinculescu, A., Timmers, A. M., Janssen, A., Tonagel, F., Tanimoto, N., Weber, B. H. F., Molday, R. S., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.002 · Cited by 174 · cited 12×
“SMD = standardized mean difference, CI = confidence interval.”
BackgroundMethodInfluentialX-linked congenital retinoschisis
Kellner, U., Br�mmer, S., Foerster, M. H., & Wessing, A. (1990) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf00927256 · Cited by 171 · cited 2×
“Around 5–20% of patients experience complications in the form of rhegmatogenous retinal detachments and/or recurrent vitreous hemorrhages, often already at a young age [3,4,9].”
BackgroundX-linked retinoschisis: an update
Sikkink, S. K., Biswas, S., Parry, N. R. A., Stanga, P. E., & Trump, D. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.047340 · Cited by 167
Exosome-associated AAV vector as a robust and convenient neuroscience tool
Hudry, E., Martin, C., Gandhi, S., György, B., Scheffer, D. I., Mu, D., Merkel, S. F., Mingozzi, F., Fitzpatrick, Z., Dimant, H., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.11 · Cited by 146
Park, T. K., Wu, Z., Kjellstrom, S., Zeng, Y., Bush, R. A., Sieving, P. A., & Colosi, P. (2009) · Gene Therapy · doi:10.1038/gt.2009.61 · Cited by 145
Tinwala, H., & Wairkar, S. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.12.073 · Cited by 131 · cited 1×
“Nevertheless, only one study used an Rs1h-deficient model to rescue RS1 [63], while the remaining three studies used WT mice in order to evaluate the success of the strategy and delivery method.”
MethodKotani, E., Yamakawa, M., Iwamoto, S.-I., Tashiro, M., Mori, H., Sumida, M., Matsubara, F., Taniai, K., Kadono‐Okuda, K., Kato, Y., et al. (1995) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(94)00202-e · Cited by 130
Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy
del Pozo‐Rodríguez, A., Solinís, M. Á., Rodríguez‐Gascón, A., & Pedraz, J. L. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.015 · Cited by 129 · cited 1×
“GFP = green fluorescent protein, h = hours.”
BackgroundWu, W. W. H., Wong, J., Kast, J., & Molday, R. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413117200 · Cited by 128
Kjellstrom, S., Bush, R. A., Zeng, Y., Takada, Y., & Sieving, P. A. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0203 · Cited by 126 · cited 7×
“Similarly, AAV5-mOP-hRS1 was used to treat mice at P15, 1 m, 2 m and 7 m, which showed that treatment efficacy declined with the age at intervention [80].”
BackgroundMethodInfluentialWu, W. W. H., & Molday, R. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302464200 · Cited by 126 · cited 1×
“The active biological conformation of the protein RS1 is a homo-oligomeric octamer that is secreted from both photoreceptors and bipolar cells [14,21–23].”
BackgroundUSE OF DORZOLAMIDE FOR PATIENTS WITH X-LINKED RETINOSCHISIS
APUSHKIN, M. A., & FISHMAN, G. A. (2006) · Retina · doi:10.1097/01.iae.0000237081.80600.51 · Cited by 119 · cited 1×
“Carbonic anhydrase inhibitors, such as dorzolamide, have been used to treat XLRS patients, by reducing the intraretinal schisis fluid cavities [37,38].”
BackgroundPhotoreceptor rescue in the RCS rat without pigment epithelium transplantation
Silverman, M. S., & Hughes, S. E. (1990) · Current Eye Research · doi:10.3109/02713689008995205 · Cited by 116 · cited 1×
“Nonetheless, the failure of IVI delivery in human clinical trials has necessitated the re-evaluation of the delivery method, also because SRI appears to be generally safe and effective in humans [107].”
BackgroundNieuwenhuis, B., Haenzi, B., Hilton, S., Carnicer-Lombarte, A., Hobo, B., Verhaagen, J., & Fawcett, J. W. (2021) · Gene Therapy · doi:10.1038/s41434-020-0169-1 · Cited by 114 · cited 1×
“Within the AAV genome, the promoter is an essential DNA regulatory element that determines where and to what degree the transgene is expressed [53].”
BackgroundTakada, Y., Fariss, R. N., Tanikawa, A., Zeng, Y., Carper, D., Bush, R., & Sieving, P. A. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0156 · Cited by 113 · cited 3×
“In the mature retina only PRs and bipolar cells are involved in RS1 synthesis, subsequently, in its secretion [18,33,34].”
BackgroundSynaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer
Ou, J., Vijayasarathy, C., Ziccardi, L., Chen, S., Zeng, Y., Marangoni, D., Pope, J. G., Bush, R. A., Wu, Z., Li, W., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81380 · Cited by 113 · cited 9×
“…of cavities 5 w, 2 m and 27 w 2 (3 experimental groups) Ou2015 [83], Vijayasarathy2022 [34] Microglial/Muller cell alterations 25 d and 35 d 2 Vijayasarathy2021 [17], Ye2022 [76] Synaptic pathology 32 w <2 m, 15 m> 3 (5 experimental groups) Takada2008 [81], Byrne2014 [54], Ou2015 [83] 3.1.7.”
BackgroundMethodInfluentialApaolaza, P. S., Delgado, D., del Pozo‐Rodríguez, A., Rodríguez‐Gascón, A., & Solinís, M. Á. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.02.038 · Cited by 108
Al-Kharashi, A., & Lam, W. (2010) · Evidence-Based Ophthalmology · doi:10.1001/archophthalmol.2009.398 · Cited by 106
Takada, Y., Vijayasarathy, C., Zeng, Y., Kjellstrom, S., Bush, R. A., & Sieving, P. A. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1071 · Cited by 100 · cited 4×
“The input parameters per experimental group are outlined in Supplementary Table S2.”
BackgroundInfluentialRetinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h−/− mouse
Byrne, L. C., Öztürk, B. E., Lee, T., Fortuny, C., Visel, M., Dalkara, D., Schaffer, D. V., & Flannery, J. G. (2014) · Gene Therapy · doi:10.1038/gt.2014.31 · Cited by 96 · cited 10×
“Despite the favorable outcomes in terms of RS1 production and secretion in Müller cells, this approach did not show reduced retinoschisis in this model [54].”
BackgroundMethodResultInfluentialJanssen, A., Min, S. H., Molday, L. L., Tanimoto, N., Seeliger, M. W., Hauswirth, W. W., Molday, R. S., & Weber, B. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.57 · Cited by 95 · cited 10×
“…Byrne2014 [54], Bush2016 [85], Maran-goni2017 [87], and Scruggs2022 [88]. studies included in this analysis were Min2005 [77], Molday2006 [78], Janssen2008 [80], Byrne2014 [54], Bush2016 [85], Marangoni2017 [87], The standardized mean di ff erences (SMDs) with 95% con fi - dence intervals (CI)…”
BackgroundMethodInfluentialPeynshaert, K., Devoldere, J., Minnaert, A.-K., De Smedt, S. C., & Remaut, K. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1565890 · Cited by 92
Delgado, D., del Pozo-Rodríguez, A., Solinís, M. Á., Avilés-Triqueros, M., Weber, B. H. F., Fernández, E., & R. Gascón, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.115 · Cited by 91
Halting progressive neurodegeneration in advanced retinitis pigmentosa
Koch, S. F., Tsai, Y.-T., Duong, J. K., Wu, W.-H., Hsu, C.-W., Wu, W.-P., Bonet-Ponce, L., Lin, C.-S., & Tsang, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82462 · Cited by 86
Bush, R. A., Zeng, Y., Colosi, P., Kjellstrom, S., Hiriyanna, S., Vijayasarathy, C., Santos, M., Li, J., Wu, Z., & Sieving, P. A. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.142 · Cited by 86 · cited 11×
“SMD = standardized mean difference, CI = confidence interval.”
BackgroundMethodInfluentialHumoral immune response after intravitreal but not after subretinal AAV8 in primates and patients
Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., et al. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22494 · Cited by 86
Intravitreal nanoparticles for retinal delivery
Huang, X., & Chau, Y. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.005 · Cited by 86
Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases
Kansara, V., Muya, L., Wan, C.-R., & Ciulla, T. A. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0126 · Cited by 84 · cited 1×
“Despite these advantages, non-viral methods have several limitations, such as treatment duration and transduction efficiency [67].”
BackgroundSequence of the Murine Factor VIII cDNA
Elder, B., Lakich, D., & Gitschier, J. M. (1993) · Genomics · doi:10.1006/geno.1993.1200 · Cited by 82 · cited 1×
“The discoidin domain mediates communication between cells and tissues [24] and is shared by several well-conserved extracellular cell surface proteins [25–31].”
BackgroundNon-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
Tolun, G., Vijayasarathy, C., Huang, R. K., Zeng, Y., Li, Y., Steven, A. C., Sieving, P. A., & Heymann, J. B. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519048113 · Cited by 79 · cited 1×
“The active biological conformation of the protein RS1 is a homo-oligomeric octamer that is secreted from both photoreceptors and bipolar cells [14,21–23].”
BackgroundGene therapy for inherited retinal diseases
Nuzbrokh, Y., Ragi, S. D., & Tsang, S. H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4726 · Cited by 79 · cited 1×
“Despite these limitations, AAVs were approved by the Food and Drug administration (FDA) and European Medicine Agency (EMA) to treat RPE65 -associated Leber’s congenital amaurosis, and are currently used in ongoing clinical trial for a broad range of inherited retinal diseases [48–51].”
BackgroundHahn, L. C., van Schooneveld, M. J., Wesseling, N. L., Florijn, R. J., ten Brink, J. B., Lissenberg-Witte, B. I., Strubbe, I., Meester‐Smoor, M. A., Thiadens, A. A. H. J., Diederen, R. M. H., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.09.021 · Cited by 78 · cited 10×
“XLRS disease severity and progression are highly variable, even among family members [4].”
BackgroundInfluentialSelf-citationThe Impact of Visual Impairment on Quality of Life.
Khorrami‐Nejad, M., Sarabandi, A., Akbari, M., & Askarizadeh, F. (2016) · Medical Hypothesis Discovery & Innovation in Ophthalmology · Cited by 77
The mouse X-linked juvenile retinoschisis cDNA: expression in photoreceptors
Reid, S. N. M., Akhmedov, N. B., Piri, N., Kozak, C. A., Danciger, M., & Farber, D. B. (1999) · Gene · doi:10.1016/s0378-1119(98)00578-2 · Cited by 76 · cited 1×
“As a consequence, RS1 is detected throughout the inner and outer mature retina as a secreted protein ([18,35].”
BackgroundAnalysis of photoreceptor function and inner retinal activity in juvenile X-linked retinoschisis
Khan, N. W., Jamison, J. A., Kemp, J., & Sieving, P. A. (2001) · Vision Research · doi:10.1016/s0042-6989(01)00188-2 · Cited by 76 · cited 2×
“…the amplitude of the dark-adapted b-wave on an electro-retinogram (ERG) is disproportionally reduced, sometimes to the extent that the ratio be-tween the band a-wave amplitudes (b/a-ratio) is below 1, and the b-wave does not cross the baseline, resulting in an ‘electronegative’ waveform [4,12].”
BackgroundKhabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A., Sahel, J., & Dalkara, D. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26031 · Cited by 71 · cited 1×
“Secondly, there was AAV7m8, which has a ten-amino acid peptide (7m8) inserted in the AAV2 protein sequence and transfects the inner and outer retina [90].”
Pennesi, M. E., Yang, P., Birch, D. G., Weng, C. Y., Moore, A. T., Iannaccone, A., Comander, J. I., Jayasundera, T., Chulay, J., Chulay, J., et al. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.06.013 · Cited by 71 · cited 1×
“However, of the eight studies describing 18 experimental groups reporting OCT data, the majority reported treatment success without quantification, showing only visual confirmation of smaller cavities in representative images.”
BackgroundYang, T.-C., Chang, C.-Y., Yarmishyn, A. A., Mao, Y.-S., Yang, Y.-P., Wang, M.-L., Hsu, C.-C., Yang, H.-Y., Hwang, D.-K., Chen, S.-J., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.10.037 · Cited by 70 · cited 4×
“List of readouts performed in in vivo studies using retinoschisin ( RS1 ) integration strategy.”
MethodInfluentialAssessment of Adeno-Associated Virus Serotype Tropism in Human Retinal Explants
Wiley, L. A., Burnight, E. R., Kaalberg, E. E., Jiao, C., Riker, M. J., Halder, J. A., Luse, M. A., Han, I. C., Russell, S. R., Sohn, E. H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.179 · Cited by 68 · cited 1×
“Thirdly, there was AAV2/4, a recombinant subtype of AAV2 that particularly transduces photoreceptors [91].”
BackgroundApaolaza, P. S., del Pozo‐Rodríguez, A., Torrecilla, J., Rodríguez‐Gascón, A., Rodríguez, J. M., Friedrich, U., Weber, B. H. F., & Solinís, M. Á. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.033 · Cited by 67 · cited 20×
“Delgado2012 [95] RS1 delivery in SLNs ARPE-19 cells CEP4-RS1 Apaolaza2015 [63] RS1 delivery in SLNs ARPE-19 cells pCAG-GFP_CMV-RS1 Wang2021 [93] RS1 delivery in exo-AAV HEK-293T cells/ARPE-19/Fibroblast cells exo-AAV2-RS1-ZsGreen These alternative delivery and non-viral delivery methods have been…”
BackgroundMethodInfluentialThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67 · cited 1×
“Post-developmental adult vector delivery at 13 weeks was able to restore RS1 expression and rescue the ERG waveform and improve the scotopic b-wave by 6 months of age, but it did not lead to any improvements in retinal morphology or photoreceptor survival [71].”
BackgroundChou, S., Yang, P., Ban, Q., Yang, Y., Wang, M., Chien, C., Chen, S., Sun, N., Zhu, Y., Liu, H., et al. (2020) · Advanced Science · doi:10.1002/advs.201903432 · Cited by 61
Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery
Bondì, M. L., Azzolina, A., Craparo, E. F., Lampiasi, N., Capuano, G., Giammona, G., & Cervello, M. (2007) · Journal of drug targeting · doi:10.1080/10611860701324698 · Cited by 61 · cited 2×
“Non-viral methods can be classified as chemical, relying on the capacity of positive lipids, peptides or polymers to introduce the negatively charged DNA of interest into cells [61] or physical, by using temperature or electrical shock to achieve nucleic acid integration [62].”
BackgroundChien, Y., Hsiao, Y.-J., Chou, S.-J., Lin, T.-Y., Yarmishyn, A. A., Lai, W.-Y., Lee, M.-S., Lin, Y.-Y., Lin, T.-W., Hwang, D.-K., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 57
Qu, Y., Liu, Y., Noor, A. F., Tran, J., & Li, R. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.250570 · Cited by 56
Vijayasarathy, C., Sui, R., Zeng, Y., Yang, G., Xu, F., Caruso, R. C., Lewis, R. A., Ziccardi, L., & Sieving, P. A. (2010) · Human Mutation · doi:10.1002/humu.21350 · Cited by 52 · cited 1×
“The function of the discoidin domain in RS1 is thought to be crucially involved in the maintenance of retinal architecture as well as synaptic connectivity between layers [11,32].”
BackgroundStingl, K., Stingl, K., Schwartz, H., Reid, M. W., Kempf, M., Dimopoulos, S., Kortuem, F., Borchert, M. S., Lee, T. C., & Nagiel, A. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.02.015 · Cited by 52 · cited 1×
“Nevertheless, AAVs also encounter some challenges, such as their high manufacturing costs, their small packaging capacity (less than 4.7 kb), and potential risks such as inflammation and retinal atrophy in the case of ocular use [44,47].”
BackgroundInfluentialTakada, Y., Fariss, R. N., Muller, M., Bush, R. A., Rushing, E. J., & Sieving, P. A. (2006) · PubMed · Cited by 50
An ENU-induced mutation in Rs1h causes disruption of retinal structure and function.
Jablonski, M. M., Dalke, C., Wang, X., Lu, L., Manly, K. F., Pretsch, W., Favor, J., Pardue, M. T., Rinchik, E. M., Williams, R. W., et al. (2005) · PubMed · Cited by 47
Verbakel, S. K., van de Ven, J. P. H., Blanc, L. M. P. L., Groenewoud, J. M. M., de Jong, E. K., Klevering, B. J., & Hoyng, C. B. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20078 · Cited by 46 · cited 2×
“Carbonic anhydrase inhibitors, such as dorzolamide, have been used to treat XLRS patients, by reducing the intraretinal schisis fluid cavities [37,38].”
BackgroundLong-term 12 year follow-up of X-linked congenital retinoschisis
Kjellström, S., Vijayasarathy, C., Ponjavic, V., Sieving, P. A., & Andréasson, S. (2010) · Ophthalmic Genetics · doi:10.3109/13816810.2010.482555 · Cited by 44 · cited 1×
“In most patients, the loss of VA progresses slowly in the first decades of life, with up to 25% of patients becoming blind by the age of 60 due to the progressive development of macular atrophy, along with retinal pigmented epithelium (RPE) dysfunction and macular pigmentary changes [4,8].”
BackgroundMultifocal ERG findings in carriers of X-linked retinoschisis
Kim, L. S., Seiple, W., Fishman, G. A., & Szlyk, J. P. (2006) · Documenta Ophthalmologica · doi:10.1007/s10633-006-9034-9 · Cited by 41 · cited 1×
“Female carriers are generally asymptomatic, although they can present with peripheral retinoschisis in rare cases [6,7].”
BackgroundZeng, Y., Petralia, R. S., Vijayasarathy, C., Wu, Z., Hiriyanna, S., Song, H., Wang, Y., Sieving, P. A., & Bush, R. A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18920 · Cited by 39 · cited 2×
“%) reported IHC findings following AAV-mediated gene augmentation therapy, of which 100% confirmed successful transgene delivery by immunostaining for RS1 [17,34,54,76–83, 85, 88 ].”
BackgroundMethodImmune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial
Mishra, A., Vijayasarathy, C., Cukras, C. A., Wiley, H. E., Sen, H. N., Zeng, Y., Wei, L. L., & Sieving, P. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.013 · Cited by 38 · cited 1×
“However, of the eight studies describing 18 experimental groups reporting OCT data, the majority reported treatment success without quantification, showing only visual confirmation of smaller cavities in representative images.”
BackgroundTesta, F., Iorio, V. D., Gallo, B., Marchese, M., Nesti, A., Rosa, G. D., Melillo, P., & Simonelli, F. (2019) · Ophthalmic Genetics · doi:10.1080/13816810.2019.1616303 · Cited by 38 · cited 1×
“This leads to an acidification of the subretinal space and, subsequently, an increased transport of fluid across the RPE, which promotes adhesion of the retinal layers [39].”
BackgroundX-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype
Khandhadia, S., Trump, D., Menon, G., & Lotery, A. J. (2011) · Eye · doi:10.1038/eye.2011.91 · Cited by 37
Applications of antisense oligonucleotides for the treatment of inherited retinal diseases
Collin, R. W. J., & Garanto, A. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000363 · Cited by 37 · cited 1×
“In addition, they allow antisense oligonucleotide introduction, an increasing avenue of interest to treat IRDs [57,60].”
BackgroundChen, D., Xu, T., Tu, M., Xu, J., Zhou, C., Cheng, L., Yang, R., Yang, T., Zheng, W., He, X., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00453 · Cited by 37
Marangoni, D., Bush, R. A., Zeng, Y., Wei, L. L., Ziccardi, L., Vijayasarathy, C., Bartoe, J. T., Palyada, K., Santos, M., Hiriyanna, S., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.11 · Cited by 36
Liu, Y., Kinoshita, J., Ivanova, E., Sun, D., Li, H., Liao, T., Cao, J., Bell, B. A., Wang, J. M., Tang, Y., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz122 · Cited by 36
Cryo-EM of retinoschisin branched networks suggests an intercellular adhesive scaffold in the retina
Heymann, J. B., Vijayasarathy, C., Huang, R. K., Dearborn, A. D., Sieving, P. A., & Steven, A. C. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201806148 · Cited by 35
Contribution to carrier detection and genetic counselling in X linked retinoschisis.
Kaplan, J., Pelet, A., Hentati, H., Jeanpierre, M., Briard, M., Journel, H., Münnich, A., & Dufier, J. (1991) · Journal of Medical Genetics · doi:10.1136/jmg.28.6.383 · Cited by 33 · cited 1×
“Female carriers are generally asymptomatic, although they can present with peripheral retinoschisis in rare cases [6,7].”
BackgroundOf men and mice: Human X-linked retinoschisis and fidelity in mouse modeling
Vijayasarathy, C., Pasha, S. P. B. S., & Sieving, P. A. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100999 · Cited by 33 · cited 3×
“…w <1 w–15 m> 2 (7 experimental groups) Janssen2008 [80], Byrne2014 [54] Presence of cavities 5 w, 2 m and 27 w 2 (3 experimental groups) Ou2015 [83], Vijayasarathy2022 [34] Microglial/Muller cell alterations 25 d and 35 d 2 Vijayasarathy2021 [17], Ye2022 [76] Synaptic pathology 32 w <2 m, 15 m> 3…”
BackgroundGenome editing via non-viral delivery platforms: current progress in personalized cancer therapy
Lan, T., Que, H., Luo, M., Zhao, X., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01550-8 · Cited by 33 · cited 1×
“These delivery systems can also be used to perform gene therapy, via gene integration, gene augmentation and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which know less safety concerns [59].”
BackgroundVijayasarathy, C., Zeng, Y., Brooks, M. J., Fariss, R. N., & Sieving, P. A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.213 · Cited by 32 · cited 31×
“Nevertheless, most studies reported a reduction in the number and size of cavities, increased or preserved retinal organization and lamination, and overall retinal thickness after treatment with AAV-mediated gene augmentation.”
BackgroundMethodInfluentialWang, W., Liu, J., Yang, M., Qiu, R., Li, Y., Bian, S., Hao, B., & Lei, B. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.328 · Cited by 30
Marangoni, D., Wu, Z., Wiley, H. E., Zeiss, C. J., Vijayasarathy, C., Zeng, Y., Hiriyanna, S., Bush, R. A., Wei, L. L., Colosi, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.067 · Cited by 29
Ye, G.-J., Conlon, T., Erger, K., Sonnentag, P., Sharma, A. K., Howard, K., Knop, D. R., & Chulay, J. D. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.077 · Cited by 28
Zeng, Y., Qian, H., Campos, M. M., Li, Y., Vijayasarathy, C., & Sieving, P. A. (2021) · Gene Therapy · doi:10.1038/s41434-021-00290-6 · Cited by 28
The role of caspases in photoreceptor cell death of the retinoschisin-deficient mouse
Gehrig, A., Janßen, A., Horling, F. M., Grimm, C., & Weber, B. H. F. (2006) · Cytogenetic and Genome Research · doi:10.1159/000094799 · Cited by 27 · cited 1×
“While non-viral vectors have been demonstrated to have lower immunogenicity and toxicity, they generally also show lower transduction efficiency; as a consequence, further optimization is still required [65,114].”
BackgroundSen, P., Agarwal, A., Bhende, P., Gopal, L., Bhende, M. P., Rishi, P., Sharma, T., & Jain, M. (2018) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_607_18 · Cited by 25 · cited 1×
“Invasive techniques like vitreoretinal surgery are only employed for patients experiencing severe complications like retinal detachments or significant epiretinal membrane of the macula [36].”
BackgroundVijayasarathy, C., Zeng, Y., Marangoni, D., Dong, L., Pan, Z., Simpson, E. M., Fariss, R. N., & Sieving, P. A. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.11.8 · Cited by 24 · cited 31×
“Nevertheless, most studies reported a reduction in the number and size of cavities, increased or preserved retinal organization and lamination, and overall retinal thickness after treatment with AAV-mediated gene augmentation.”
BackgroundMethodInfluentialERG Responses in Mice with Deletion of the Synaptic Ribbon Component RIBEYE
Fairless, R., Williams, S. K., Katiyar, R., Maxeiner, S., Schmitz, F., & Diem, R. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.5.37 · Cited by 19 · cited 1×
“The a-wave on an ERG is believed to An electronegative ERG is thought to imply a de fi ciency of synaptic signal propagation between the PRs and the bipolar cells [13]. represent photoreceptor (PR) function, whereas the b-wave is indicative of ON bipolar cell activity.”
BackgroundRapid resolution of retinoschisis with acetazolamide
Zhang, L., Reyes, R. E. R., Lee, W., Chen, C., Chan, L., Sujirakul, T., Chang, S., & Tsang, S. H. (2015) · Documenta Ophthalmologica · doi:10.1007/s10633-015-9496-8 · Cited by 17
Hensman, J., Hahn, L. C., van Schooneveld, M. J., Diederen, R. M. H., ten Brink, J. B., Florijn, R. J., Bergen, A. A. B., Strubbe, I., Heutinck, P. A. T., van Genderen, M. M., et al. (2023) · Ophthalmology Retina · doi:10.1016/j.oret.2023.12.003 · Cited by 17 · cited 1×
“These medications may achieve a variable amount of reduction in schisis cavities in XLRS, but without marked improvements in VA [38–43].”
BackgroundSelf-citationAAV2/4-RS1 gene therapy in the retinoschisin knockout mouse model of X-linked retinoschisis
Scruggs, B. A., Bhattarai, S., Helms, M., Cherascu, I., Salesevic, A., Stalter, E., Laird, J. G., Baker, S. A., & Drack, A. V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276298 · Cited by 14 · cited 8×
“SMD = standardized mean difference, CI = confidence interval.”
BackgroundMethodInfluentialDisease Mechanisms and Gene Therapy in A Mouse Model for X-Linked Retinoschisis
Molday, L. L., Min, S.-H., Seeliger, M. W., Wu, W. W. H., Dinculescu, A., Timmers, A. M., Janßen, A., Tonagel, F., Hudl, K., Weber, B. H. F., et al. (2007) · Springer eBooks · doi:10.1007/0-387-32442-9_39 · Cited by 13 · cited 7×
“The ideal therapy resolves cavity formation, protects the integrity of lamination, prevents ONL degradation and rescues retinal function.”
BackgroundInfluentialKirkby, J., Halford, S., Shanks, M. E., Moore, A. T., Gait, A., Jenkins, L., Clouston, P., Patel, C. K., & Downes, S. M. (2023) · Genes · doi:10.3390/genes14061193 · Cited by 10 · cited 1×
“Nevertheless, homozygous females have shown a XLRS phenotype, and heterozygous females can very rarely also show XLRS features as a consequence of X-chromosome inactivation [3,5].”
BackgroundXLRS Rat with Rs1-/Y Exon-1-Del Shows Failure of Early Postnatal Outer Retina Development
Ye, E., Zeng, Y., Thomas, S., Sun, N., Smit‐McBride, Z., & Sieving, P. A. (2022) · Genes · doi:10.3390/genes13111995 · Cited by 8 · cited 10×
“…groups) Min2005 [77], Molday2006 [78], Kjellstrom2007 [79], Janssen2008 [80], Takada2008 [81], Park2009 [82], Byrne2014 [54], Ou2015 [83], Bush2016 [85], Vijayasarathy2021 [17], Scruggs2022 [75], Ye2022 [76], Vijayasarathy2022 [34] Laminar organization and integrity 32 w <25 d–15 m> 2…”
BackgroundMethodInfluentialMarangoni, D., Yong, Z., Kjellström, S., Vijayasarathy, C., Sieving, P. A., & Bush, R. A. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21016 · Cited by 5 · cited 13×
“SMD = standardized mean difference, CI = confidence interval.”
BackgroundMethodInfluential
Research works printed but not linked: 1
- Haas J. Ueber das Zusammenvorkommen von Veraenderungen der Retina und Choroidea Arch. Augenheilkd. 1898 37 343 348
Cited by
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“For example, X-linked retinoschisis demonstrates increased retinal fragility, making the detachment of posterior hyaloid and subretinal injection highly challenging (van der Veen et al., 2024).”
A Comparative Analysis of Models for AAV-Mediated Gene Therapy for Inherited Retinal Diseases
Alsalloum, A., Gornostal, E. A., Mingaleva, N., Pavlov, R. E., Kuznetsova, E., Antonova, E., Nadzhafova, A., Колотова, Д. Е., Кадышев, В. В., Mityaeva, O. N., et al. (2024) · Cells · doi:10.3390/cells13201706 · Cited by 20
Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review
Kharisova, C. B., Kitaeva, K. V., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., Ахметшин, Р. Ф., Bulgar, S. N., & Rizvanov, A. A. (2025) · Biomedicines · doi:10.3390/biomedicines13020365 · Cited by 19
“To date, seven clinical trials of gene therapy for achromatopsia have been registered: NCT03278873, NCT02610582, NCT02610582, and NCT02599922, in addition to one that has been completed [NCT04124185] and two that have published results [NCT03001310 and NCT03758404].”
Hensman, J., Allali, Y. E., Almushattat, H., de Vente, C., Sánchez, C. I., & Boon, C. J. F. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17495 · Cited by 7
“adeno-associated virus (AAV)- mediated gene therapy have exhibited encouraging therapeutic outcomes, suggesting potential therapeutic options leading to several ongoing clinical phase I/II gene therapy studies (Byrne et al., 2014; van der Veen et al., 2024).”
Self-citationA retrospective longitudinal study of 52 Finnish patients with X‐linked retinoschisis
Järvinen, M. A., Baraas, R. C., Majander, A. S., Backlund, M., Krootila, J., Paavo, M., Lindahl, P., Vasara, K., Sankila, E., Kivelä, T., et al. (2024) · Acta Ophthalmologica · doi:10.1111/aos.16776 · Cited by 7
Metadata
- Authors
- van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F.
- Affiliations
- Department of Ophthalmology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- Amsterdam UMC Location University of Amsterdam (NL)
- Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- Leiden University (NL)
- Corresponding author
- Boon, Camiel J. F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-01-19
- Volume
- 25
- Issue
- 2
- Pages
- 1267
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10816913
- OpenAlex
- W4391107036
- Cited by
- 14
- References
- 120
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 2
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- Funders
- NWO-ALW (Nederlandse Organisatie voor Wetenschappelijk Onderzoek-Aard en Levenswetenschappen) (09150171910048)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- X-linked retinoschisis, retinoschisin, RS1, gene therapy, gene augmentation therapy, adeno-associated virus vectors, viral vectors, non-viral gene delivery, rodent models, cell-based models, electroretinogram, retinal function, risk of bias assessment
- MeSH terms
- Animals, Electroretinography, Eye Proteins, Humans, Male, Mutation, Retina, Genetic Therapy, Retinoschisis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.